<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052986</url>
  </required_header>
  <id_info>
    <org_study_id>VCT-01</org_study_id>
    <nct_id>NCT02052986</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels</brief_title>
  <acronym>CARE</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>New York Hospital Queens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NYHQ Cardiac Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pivotal Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York Hospital Queens</source>
  <brief_summary>
    <textblock>
      The investigators aim to test the hypothesis that dietary supplementation with VASCAZEN will
      correct omega-3 deficiency in cardiac rehab patients and improve biochemical risk factors.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sum of Omega-Score and Omega-Index</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in the sum of the subject's blood Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) + Docosapentaenoic acid (DPA) levels (Omega-Score) and the change in the sum of the subject's red blood cell (RBC) EPA + DHA levels (Omega-Index) over 12 weeks of study treatment with Vascazen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in patient health questionnaire-9 (PHQ-9) depression scale</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in patient health questionnaire-9 (PHQ-9) depression scale after 12 weeks of study treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Omega-3 Score and Omega-3 Index</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in high-sensitivity C-reactive protein (hsCRP)</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in blood levels of total cholesterol, low-density lipoprotein (LDL), high density lipoprotein (HDL), very-low density lipoprotein (VLDL) cholesterol and their subfractions (particle size)</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in blood level of Triglycerides</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in fasting plasma glucose</measure>
    <time_frame>Baseline,12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in blood glucose and insulin measurements following administration of oral glucose tolerance test (OGTT)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in glycated hemoglobin (HbA1c)</measure>
    <time_frame>Baseline,12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Lipoprotein associated Phospholipase (Lp-PLA2)</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Vascazen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will receive four capsules daily of VASCAZEN (a 3.0 gram daily dose of EPA+DHA) for a total of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VASCAZEN</intervention_name>
    <description>All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA</description>
    <arm_group_label>Vascazen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (&gt; or = 18 years of age)

          -  Enrolled in Cardiac Rehabilitation clinic with documented cardiovascular disease as
             assessed by the principle investigator

          -  Has had cardiovascular examination within the past 2 months

        Exclusion Criteria:

          -  Subjects who refuse to provide written consent

          -  Subjects with medical conditions, as determined by the principal investigator, which
             prevented them from study participation

          -  Subjects with a known bleeding or clotting disorder

          -  Subjects with known allergies to fish

          -  Subjects with an implantable cardiac defibrillator

          -  Subjects with a heart transplant

          -  Female subjects who are currently taking hormone replacement therapy

          -  Subjects who are pregnant or planning on becoming pregnant

          -  Subjects currently taking Omega-3 fatty acid supplements (either under medical
             supervision or self-administered)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian S Marino, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Hospital Queens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian S Marino, DO</last_name>
    <phone>814-404-4169</phone>
    <email>brm9071@nyp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna Cheslik, RN, MSN</last_name>
    <phone>718-670-1695</phone>
    <email>djc9001@nyp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The NYHQ Cardiac Health Center</name>
      <address>
        <city>Fresh Meadows</city>
        <state>New York</state>
        <zip>11365</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Marino, DO</last_name>
      <phone>814-404-4169</phone>
      <email>brm9071@nyp.org</email>
    </contact>
    <investigator>
      <last_name>Todd Kerwin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Pistone, RD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.webmd.com/drugs/drug-160617-Vascazen+Oral.aspx?drugid=160617&amp;drugname=Vascazen+Oral</url>
    <description>WebMD</description>
  </link>
  <reference>
    <citation>Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002 Apr 11;346(15):1113-8.</citation>
    <PMID>11948270</PMID>
  </reference>
  <reference>
    <citation>Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999 Aug 7;354(9177):447-55. Erratum in: Lancet 2001 Feb 24;357(9256):642. Lancet. 2007 Jan 13;369(9556):106.</citation>
    <PMID>10465168</PMID>
  </reference>
  <reference>
    <citation>Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol. 2006 Aug 21;98(4A):71i-76i. Epub 2006 May 30. Review.</citation>
    <PMID>16919519</PMID>
  </reference>
  <reference>
    <citation>Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000 May;71(5):1085-94.</citation>
    <PMID>10799369</PMID>
  </reference>
  <reference>
    <citation>Grimsgaard S, Bonaa KH, Hansen JB, Nord√∏y A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. 1997 Sep;66(3):649-59.</citation>
    <PMID>9280188</PMID>
  </reference>
  <reference>
    <citation>Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002 Aug;20(8):1493-9.</citation>
    <PMID>12172309</PMID>
  </reference>
  <reference>
    <citation>Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003 Feb 8;361(9356):477-85.</citation>
    <PMID>12583947</PMID>
  </reference>
  <reference>
    <citation>Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002 Nov 19;106(21):2747-57. Erratum in: Circulation. 2003 Jan 28;107(3):512..</citation>
    <PMID>12438303</PMID>
  </reference>
  <reference>
    <citation>Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004 Jul;39(1):212-20.</citation>
    <PMID>15208005</PMID>
  </reference>
  <reference>
    <citation>von Schacky C, Harris WS. Cardiovascular risk and the omega-3 index. J Cardiovasc Med (Hagerstown). 2007 Sep;8 Suppl 1:S46-9. Review.</citation>
    <PMID>17876200</PMID>
  </reference>
  <reference>
    <citation>Derosa G (2011) Effects of n-3 PUFA on Insulin Resistance After an Oral Fat Load. European Journal of Lipid Science. 113: (8) 950-960</citation>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <last_update_submitted>January 31, 2014</last_update_submitted>
  <last_update_submitted_qc>January 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Hospital Queens</investigator_affiliation>
    <investigator_full_name>Brian S. Marino, DO</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Fatty Acids, Omega-3</keyword>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Docosahexaenoic acid (DHA)</keyword>
  <keyword>Eicosapentaenoic acid (EPA)</keyword>
  <keyword>Docosapentaenoic acid (DPA)</keyword>
  <keyword>Omega Index</keyword>
  <keyword>Omega Score</keyword>
  <keyword>Cardiac Rehab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

